Skip to main content
. 2018 Feb 16;8:3212. doi: 10.1038/s41598-018-20811-5

Figure 6.

Figure 6

In a 4-day murine bleomycin injury model in therapeutic treatment mode, AD-114-6H reduced the % of Col1+/CD45+/CXCR4+ cells and CXCL12 content in the lungs, and modulated the expression of col1a1, col3a1 and cxcl12 genes. Following intratracheal instillation of bleomycin, mice were injected daily for 4 days with vehicle, AD-114-6H, negative i-body, AMD3100 or pirfenidone. Cell suspensions from minced lung tissue were evaluated by flow cytometry for Col1+/CD45+/CXCR4+ cell content (A) and by qPCR for expression of genes encoding col1a1, col3a1 and cxcl12 (CE), and the CXCL12 soluble protein content in the lung bronchoalveolar lavage (BAL) fluid was quantified by ELISA (B). N = 10 mice per group, error bars show S.E. Statistical significance if any is shown as *p = < 0.05, **p = < 0.01 or ****p = < 0.0001 as determined following testing of Vehicle mean against treatment means using a One-way ANOVA, Dunnett’s posthoc test.